Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry.
Mountzios G, Planchard D, Metro G, Tsiouda D, Prelaj A, Lampaki S, Shalata W, Riudavets M, Christopoulos P, Girard N, Albarrán-Artahona V, Garcia Campelo R, Samitas K, Banna GL, Boukovinas I, Agbarya A, Koumarianou A, Perdikouri EI, Kosmidis P, Linardou H, Mauri D, Mavroudis D, Athanasiadis I, Kalofonos H, Xenidis N, Korantzis I, Ardavanis A, Rallis G, Bottiglieri A, Efthymiadis K, Oikonomopoulos G, Kokkalis A, Saloustros E, Tsoukalas N, Bartzi D, Economopoulou P, Psyrri A, Reck M, Lo Russo G. Mountzios G, et al. Among authors: metro g. JTO Clin Res Rep. 2022 Nov 20;4(1):100433. doi: 10.1016/j.jtocrr.2022.100433. eCollection 2023 Jan. JTO Clin Res Rep. 2022. PMID: 36793384 Free PMC article.
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.
Metro G, Addeo A, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Rey Cobo J, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Garassino MC, Mountzios G. Metro G, et al. J Thorac Dis. 2019 Dec;11(12):4972-4981. doi: 10.21037/jtd.2019.12.23. J Thorac Dis. 2019. PMID: 32030213 Free PMC article.
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.
Friedlaender A, Metro G, Signorelli D, Gili A, Economopoulou P, Roila F, Banna G, De Toma A, Camerini A, Christopoulou A, Lo Russo G, Banini M, Galetta D, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Mountzios G, Garassino MC, Addeo A. Friedlaender A, et al. Among authors: metro g. Acta Oncol. 2020 Sep;59(9):1058-1063. doi: 10.1080/0284186X.2020.1781249. Epub 2020 Jun 17. Acta Oncol. 2020. PMID: 32762415
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab.
Banna GL, Signorelli D, Metro G, Galetta D, De Toma A, Cantale O, Banini M, Friedlaender A, Pizzutillo P, Garassino MC, Addeo A. Banna GL, et al. Among authors: metro g. Transl Lung Cancer Res. 2020 Aug;9(4):1533-1542. doi: 10.21037/tlcr-19-583. Transl Lung Cancer Res. 2020. PMID: 32953525 Free PMC article.
Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients.
Britschgi C, Addeo A, Rechsteiner M, Delaloye R, Früh M, Metro G, Banini M, Gautschi O, Rothschild SI, Wild PJ, Banna GL, Curioni-Fontecedro A. Britschgi C, et al. Among authors: metro g. Front Oncol. 2020 Aug 21;10:1299. doi: 10.3389/fonc.2020.01299. eCollection 2020. Front Oncol. 2020. PMID: 32974130 Free PMC article.
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%.
Metro G, Banna GL, Signorelli D, Gili A, Galetta D, Galli G, Economopoulou P, Roila F, Friedlaender A, Camerini A, Christopoulou A, Cantale O, De Toma A, Pizzutilo P, Jimenez B, Collazo-Lorduy A, Calles A, Baxevanos P, Linardou H, Kosmidis P, Giannarelli D, Mountzios G, Addeo A. Metro G, et al. J Immunother. 2020 Nov/Dec;43(9):299-306. doi: 10.1097/CJI.0000000000000340. J Immunother. 2020. PMID: 32991393
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
Mountzios G, de Toma A, Economopoulou P, Friedlaender A, Banini M, Lo Russo G, Baxevanos P, Roila F, Banna GL, Christopoulou A, Jimenez B, Collazo-Lorduy A, Linardou H, Calles A, Galetta D, Addeo A, Camerini A, Pizzutilo P, Kosmidis P, Garassino MC, Proto C, Signorelli D, Metro G. Mountzios G, et al. Among authors: metro g. Clin Lung Cancer. 2021 Mar;22(2):e180-e192. doi: 10.1016/j.cllc.2020.09.017. Epub 2020 Oct 14. Clin Lung Cancer. 2021. PMID: 33162330
183 results